Autonomic Dysfunction Archives - Page 3 of 8 - Dr. Nicholas L. DePace, M.D., F.A.C.C.

Jun 29 0

Coronavirus Induces Oxidative Stress Leading to Autonomic Dysfunction – Part 5

Posted by joeobiso

Click here to download the full 5 Part Article

Notes: This is the fifth in a series of 5 blog posts about COVID-19 and Autonomic Dysfunction. This a pre-publication release that will be featured in a major medical journal.

Coronavirus Induces Oxidative Stress Leading to Autonomic Dysfunction Often With Delayed Symptom Onset

Heather L. Bloom, MD¹ and Joseph Colombo, PhD, DNM, DHS²

Electrophysiology, Atlanta Veterans Affairs Medical Center and Emory University Medical School, Atlanta, GA bloom@gmail.com
Parasympathetic & Sympathetic Nervous System Consultant, Franklin Cardiovascular Associates, PA & Autonomic Dysfunction and POTS Center, Sewell, NJ, and Senior Medical Director & CTO, Physio PS, Inc., Atlanta, GA, dovetech@erols.com

Correspondence should be addressed to Dr. Colombo, dovetech@erols.com

CONCLUSIONS

In all, poor brain and cardiac perfusion is often the result of Oxidative Stress mediated P&S Dysfunction and if both are not treated they will augment and amplify each other and their resulting symptoms. Unfortunately, most of the therapies for P&S Dysfunction are off-label. Also, they are most effective at low doses. High doses cause side effects which lead to or are caused by additional P&S Dysfunctions which are induced by these high dose pharmaceuticals. Fortunately, Antioxidants are known to also help treat P&S Dysfunction as well as Oxidative Stress. Either way, P&S monitoring provides an objective, scientifically-based, outcomes-driven assessment of the individual patient’s responses to disease, disorder and therapy. This helps to titrate therapy specifically for the individual patient, using the individual as their own baseline. This also helps to identify medications that are not helping and perhaps may be harming the patient.

Relieving Oxidative Stress and the associated P&S Dysfunction helps to relieve lightheadedness and dizziness, fatigue, sleep difficulties, GI symptoms (upper or lower), Anxiety/Depression, difficult to control BP, blood glucose or hormone levels, headache or migraine, brain-fog, cognitive or memory difficulties, etc. In doing so, patients have improved quality of life and productivity, improved outcomes, reduced hospitalizations and re-hospitalizations, and thereby reduced healthcare costs. The additional information from P&S Monitoring with therapy individualized for the patient helps physicians go beyond merely managing the disorder, helping physicians to restore health and promote wellness as well.

DATA AVAILABILITY

Patient data are from patient records and files and are therefore HIPAA protected. Therefore, data availability is limited. You may contact the corresponding author to request access and limited access may be granted.

CONFLICTS OF INTEREST

Dr. Bloom has no conflicts of interest. Dr. Colombo is Senior Medical Director and Chief Technology Officer of Physio PS, Inc., the provider of the P&S Monitoring technology.

FUNDING

This project was not funded under any grant or contract.

REFERENCES

_________________

[1] Murray GL. COVID-19 cardiac complications: Is an easy, safe treatment strategy right under our noses? J Cardiovasc Dis Diag. 2020; 8:5. doi: 10.37421/jcdd.2020.8.415.

2 DePace NL, Colombo J. Autonomic and Mitochondrial Dysfunction in Clinical Diseases: Diagnostic, Prevention, and Therapy. Springer Science + Business Media, New York, NY, 2019.

3 Acosta C, DePace NL, DePace NL, Kaczmarski K, Pinales JM, and Colombo J. Antioxidants effect changes in systemic parasympathetic and sympathetic nervous system responses and improve outcomes. Cardio Open. 2020; 5(1): 26-36. doi: 10.33140/COA.05.01.04

⁴Colombo J, Arora RR, DePace NL, Vinik AI. Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes. Springer Science + Business Media, New York, NY, 2014.

5 Vinik A, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007; 115: 387-397.

6 Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocrine Disease. 2007; Dec: 2-9.

7 Malik, M. The Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability, standards of measurement, physiological interpretation, and clinical use. Circulation. 1996; 93:1043-1065.

⁸ Malik, M. and the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability, standards of measurement, physiological interpretation, and clinical use. European Heart Journal. 1996, 17: 354-381.

⁹ Akselrod S, Oz O, Greenberg M, Keselbrener L. Autonomic response to change of posture among normal and mild-hypertensive adults: investigation by time-dependent spectral analysis. J Auton Nerv Syst. 1997 May 12;64(1):33-43.

¹⁰ Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and Cardiovascular Disease. JACC. 2018; 71(20): 2346-2359.

1¹ Arora RR, Bulgarelli RJ, Ghosh-Dastidar S, Colombo J. Autonomic mechanisms and therapeutic implications of postural diabetic cardiovascular abnormalities. J Diabetes Science and Technology. 2008; 2(4): 568-71.

12 DePace NL, Vinik AI, Acosta C and Colombo J. Oral vasoactive medications: A Review of Midodrine, Droxidopa, and Pseudoephedrine as Applied to Orthostatic Dysfunction. NEJM. 2020. Submitted.

¹³ Vinik AI, Bloom HL, Colombo J. Differential effects of adrenergic antagonists (carvedilol vs. metoprolol) on parasympathetic and sympathetic activity: A comparison of measures. Heart International. Heart Int. 2014; 9(1): 7-14; DOI: 10.5301/HEART.2014.12495.

¹⁴ Bloom HL, Vinik AI, Colombo J. Differential effects of adrenergic antagonists (carvedilol vs. metoprolol) on parasympathetic and sympathetic activity: A comparison of clinical results. Heart Int. 2014 ; 9 (1): 15-21; DOI: 10.5301/HEART.2014.12496.

¹⁵ Murray GL and Colombo J. (R)Alpha Lipoic Acid is a Safe, Effective Pharmacologic Therapy of Chronic Orthostatic Hypotension Associated with Low Sympathetic Tone. Int J Angiol. In Print, 2018.

KEY WORDS

Coronavirus, Parasympathetic, Sympathetic, Oxidative Stress, Antioxidants

ABBREVIATIONS

ALA Alpha-Lipoic Acid

ANS Autonomic Nervous System

CoQ10 Co-enzyme Q10

COVID-19 Coronavirus (SARS-CoV-2)

P&S Parasympathetic and Sympathetic

PE Parasympathetic Excess

POTS Postural Orthostatic Tachycardia Syndrome

SE Sympathetic Excess

SW Sympathetic Withdrawal

[i] Colombo J, Arora RR, DePace NL, Vinik AI. Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes. Springer Science + Business Media, New York, NY, 2014.

[ii] Vinik A, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007; 115: 387-397.

[iii] Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocrine Disease. 2007; Dec: 2-9.

[iv] Malik, M. The Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability, standards of measurement, physiological interpretation, and clinical use. Circulation. 1996; 93:1043-1065.

[v] Malik, M. and the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability, standards of measurement, physiological interpretation, and clinical use. European Heart Journal. 1996, 17: 354-381.

[vi] Akselrod S, Oz O, Greenberg M, Keselbrener L. Autonomic response to change of posture among normal and mild-hypertensive adults: investigation by time-dependent spectral analysis. J Auton Nerv Syst. 1997 May 12;64(1):33-43.

Jun 15 1

Coronavirus Induces Oxidative Stress Leading to Autonomic Dysfunction – Part 4

Posted by joeobiso

Click here to download this post

Notes: This is the fourth in a series of 5 blog posts about COVID-19 and Autonomic Dysfunction. This a pre-publication release that will be featured in a major medical journal.

Coronavirus Induces Oxidative Stress Leading to Autonomic Dysfunction Often With Delayed Symptom Onset

Heather L. Bloom, MD¹ and Joseph Colombo, PhD, DNM, DHS²

Electrophysiology, Atlanta Veterans Affairs Medical Center and Emory University Medical School, Atlanta, GA bloom@gmail.com
Parasympathetic & Sympathetic Nervous System Consultant, Franklin Cardiovascular Associates, PA & Autonomic Dysfunction and POTS Center, Sewell, NJ, and Senior Medical Director & CTO, Physio PS, Inc., Atlanta, GA, dovetech@erols.com

Correspondence should be addressed to Dr. Colombo, dovetech@erols.com

THERAPY OPTIONS

In general, Oxidative Stress is treated with Antioxidants; more on this below in the Non-Pharmaceutical section. Non-pharmaceutical therapy is often the primary P&S therapy which may often be accelerated with pharmaceutical therapy. Often, once P&S balance is re-established, assuming no end-organ dysfunction, the P&S will carry forward independent of pharmaceutical therapy and only non-pharmaceutical, maintenance therapy may be required. This is typically in the form of Antioxidants to help maintain proper Antioxidant levels in the body. With chronic disease or disorder, as with aging, antioxidants are depleted in the body and production is slowed; therefore, supplemental therapy is needed.

Pharmaceutical Therapy Options

Pharmaceutical therapy options are recommended based on patient history [[i]]. In general they included the following. For SW, 2.5 mg Midodrine titrated slowly, as needed, from qd to tid. For Orthostatic Hypotension, including pre-clinical cases, the first dose is recommended around dinner, four hours before laying down, when BP tended to be lowest. For POTS patients, morning doses are recommended since symptoms are typically more significant at that time. Midodrine is contraindicated for patients with supine hypertension and for patients with resting BPs higher than 160/90 mmHg [[ii]]. Some patients do not respond to, or are contra-indicated for, Midodrine. While Northera is the recommended alternate, it is very expensive and 30 to 60 mg Mestinon, qd, is recommended as the first alternate. Only if patients are unresponsive to Mestinon is Northera considered, but still must be approved. Non-pharmaceutical alternates are discussed below. Low dose Fludrocortisone or Pseudoephedrine may be suitable adjunctives [[iii]].

Note, if patients present with SW and high BP, the high BP is (at least in part) compensatory for the associated Orthostatic Hypotension. In these cases treating the Hypertension as the primary typically confounds the condition and may even cause BP to increase, as the poor brain perfusion is exacerbated and the body defeats the therapy. In most cases, relieving SW organically reduces BP [11] and any remaining Hypertension may then be treated as the primary, once the patient’s P&S nervous systems stabilize.

For PE low-dose anti-cholinergic therapy (very low dose antidepressant therapy) is recommended. For example, no more than 10.0 mg, qd, dinner Nortriptyline (primary) or 20mg, qd, Duloxetine (secondary) is recommended. Clinical doses of these pharmaceuticals will exacerbate the condition with additional symptoms. Often patients that present with long standing PE, who have been referred for Psych-eval and have been prescribed much higher doses of these pharmaceuticals, or have been prescribed antidepressants for more than six months with little or no relief, no longer respond or tolerate the recommended low-dose anti-cholinergic therapy, and alternate therapies are needed. The primary alternate anti-cholinergic therapy recommended is “Low-and-Slow” exercise (see below) and was also recommended to help re-condition the heart muscle for improved cardiac output and thereby improved brain perfusion. The recommended anti-cholinergic therapy tends to have little effect on BP and helps to pattern sleep. If a more potent anti-cholinergic is needed and weight-gain is not a problem, 10.0 mg, qd, dinner Amitriptyline is recommended.

If PE presents with SE and with established Hypertension or Cardiovascular Disease, then low-dose or dose equivalent Carvedilol is recommended. Carvedilol treats all three simultaneously. It is not only a beta-blocker, but it is also an antioxidant [[iv],[v]].

Note, PE often causes secondary SE. SE may lead to hypertension. In these cases, treating the Hypertension as the primary exacerbates the Hypertension, similar to SW. In most cases, relieving PE organically relieves SE (after a few months) which, in turn, organically reduces BP [2] and any remaining Hypertension may then be treated as the primary, once the patient’s P&S nervous systems stabilize.

For (stand) SE, therapy depends on the differential. If SE is demonstrated with PE indicating (pre-clinical) Vasovagal Syncope, then PE therapy is followed as the primary and typically the SE is relieved organically. If SE is demonstrated with a drop in HR from resting to stand indicating (pre-clinical) Neurogenic Syncope, volume building and often Midodrine helps to treat the stand SE. Any remaining SE indicates (by omission) possible Cardiogenic Syncope and more testing is required to diagnose and treat. [4]

Autonomically mediated arrhythmia, with or without SE may be documented. Autonomically mediated arrhythmia is associated with inefficient circulation and may be another result of Oxidative Stress. Autonomically mediated arrhythmia with SE may contribute to Cardiogenic syncope, and treating SE may help to relieve the arrhythmia. Autonomically mediated arrhythmia with PE may contribute to Vasovagal Syncope, and treating SE may help to relieve the arrhythmia. Autonomically mediated arrhythmia with normal Sympathovagal Balance (SB = S/P, a resting baseline measurement), the arrhythmia is not autonomic and further testing maybe required to diagnose and treat. [4]

Non-Pharmaceutical Therapy Options

In general, Psychosocial Stress reduction is recommended with history-specific Antioxidant and Nitric Oxide supplement recommendations to reduce Oxidative Stress and improve blood flow [4]. Nitric Oxide also has Antioxidant properties. Non-Pharmaceutical therapy options are recommended if patients are intolerant or unresponsive to the pharmaceutical options.

Alpha-Lipoic Acid (ALA) and Co-Enzyme Q10 (CoQ10) are two of the most potent Antioxidants made in the body. ALA tends to be more selective for nerves. CoQ10 tends to be more selective for cardiac tissue. Both help to recycle other Antioxidants, including Vitamins A, C & E, and Glutathione. Specifically for SW, 600 mg tid, Alpha-Lipoic Acid, titrated as needed and tolerated [[vi]], is recommended. Exercise is arguably the most potent Antioxidant available. For PE (which is an autonomic state that amplifies the stress response of all stressors including healthy stressors such as exercise), six months of “Low-and-Slow” exercise is recommended to retrain the nervous system to accept small, healthy stresses before more significant stresses may be tolerated. Low-and-Slow exercise is characterized by walking at no more than 2 mph for 40 contiguous minutes per day, for 6 months (suitable alternates include slow motion rowing, or slow motion bicycling or pedaling are options) [4]. Exercise that breaks down muscle or connective tissue or that raises HR and BP too fast should be strictly avoided. Often “Low-and-Slow” exercise is augmented, especially if the patient reported significant sleep difficulties, by 20 minutes of supine, 15° head-down posture around two hours before bed-time and up to three times per day, as needed, but in any instance, at least 2 hours after low-dose Midodrine dosing. Patients who are too lightheaded to sit up or too exercise intolerant may perform supine Low-and-Slow exercise by lying on the floor next to the bed with their lower legs on the bed, and only move their lower legs like they were walking at 2 mph, for the prescribed 40 minutes (see insert).

[i] Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and Cardiovascular Disease. JACC. 2018; 71(20): 2346-2359.

[ii] Arora RR, Bulgarelli RJ, Ghosh-Dastidar S, Colombo J. Autonomic mechanisms and therapeutic implications of postural diabetic cardiovascular abnormalities. J Diabetes Science and Technology. 2008; 2(4): 568-71.

[iii] DePace NL, Vinik AI, Acosta C and Colombo J. Oral vasoactive medications: A Review of Midodrine, Droxidopa, and Pseudoephedrine as Applied to Orthostatic Dysfunction. NEJM. 2020. Submitted.

[iv] Vinik AI, Bloom HL, Colombo J. Differential effects of adrenergic antagonists (carvedilol vs. metoprolol) on parasympathetic and sympathetic activity: A comparison of measures. Heart International. Heart Int. 2014; 9(1): 7-14; DOI: 10.5301/HEART.2014.12495.

[v] Bloom HL, Vinik AI, Colombo J. Differential effects of adrenergic antagonists (carvedilol vs. metoprolol) on parasympathetic and sympathetic activity: A comparison of clinical results. Heart Int. 2014 ; 9 (1): 15-21; DOI: 10.5301/HEART.2014.12496.

[vi] Murray GL and Colombo J. (R)Alpha Lipoic Acid is a Safe, Effective Pharmacologic Therapy of Chronic Orthostatic Hypotension Associated with Low Sympathetic Tone. Int J Angiol. In Print, 2018.